Podcast

Finding a Way Forward in Blood Cancer

Author(s):

Jessica Skarzynski

Information about myeloproliferative neoplasms – or MPNs – is hard to come by. But the MPN Research Foundation’s myMPN Patient Registry aims to change that. Learn more about it in this week's episode of the CURE Talks Cancer podcast.

Information about myeloproliferative neoplasms — or MPNs – is hard to come by. Even a simple internet search about this rare group of blood cancers turns up little. But the MPN Research Foundation’s myMPN Patient Registry aims to change that.

This week on CURE Talks Cancer, we spoke with Robyn M. Scherber, Assistant Professor of Medicine in the Department of Hematology and Oncology at the UT Health San Antonio MD Anderson Cancer Center; Lindsey Whyte, myMPN Project Manager of the MPN Research Foundation; and Michelle Woehrle, Executive Director of the MPN Research Foundation about their work with the registry, and about a recent patient data analysis that is helping to shed new light on this family of diseases.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Image of Crispino
Picture of Joy Anderson
Image of doctor.
Dr. Richard “Rick" Winneker
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with grey hair.
Image of bald man in suit.
Related Content
Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis: © stock.adobe.com
April 19th 2025

Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis

Alex Biese
Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of blood cells.
March 16th 2025

Jakafi May Not Associate with Long-Term Benefits in Myelofibrosis Subset

Spencer Feldman
Real-world data suggest Jakafi shows limited benefits in CALR-mutated myelofibrosis.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Illustration of red blood cells.
January 20th 2025

Subcutaneous Dacogen Elicits Responses Among Some With Myelofibrosis

Alex Biese
Ten days of subcutaneous Dacogen resulted in responses among a third of patients with myelofibrosis.
Illustration of red blood cells.
January 10th 2025

P1101 Treatment Meets Phase 3 Primary End Point in Essential Thrombocythemia

Ryan Scott
P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the primary end goal of SURPASS-ET.